Broadwood Capital Inc.
Broadwood Capital Inc. reported 6 US-listed holdings worth $1.91 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Monster Beverage Corp. (40.7%), Staar Surgical Co. (24.2%) and Axon Enterprise, Inc. (20.3%). Against the quarter before, it opened 0 positions, added to 1, trimmed 0 and sold out of 0.
Reported holdings$1.91B+34.8% on Q1 2026
Positions6as many as Q1 2026
The largest ten100.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Added toHeld
The 6 largest of its 6 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Added 1Held 5
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Added to 1
- Oncocyte Corp IMDX+753,045 shares · +6%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Monster Beverage Corp. MNST | 8,107,796 | $779.3 million | 40.73% | no change |
| Staar Surgical Co. STAA | 16,123,842 | $462.6 million | 24.18% | no change |
| Axon Enterprise, Inc. AXON | 693,504 | $388.8 million | 20.32% | no change |
| iShares Russell 2000 ETF IWM | 474,920 | $142.7 million | 7.46% | no change |
| Oncocyte Corp IMDX | 12,684,884 | $74.8 million | 3.91% | +753,045 |
| Lineage Cell Therapeutics in LCTX | 49,560,992 | $64.9 million | 3.39% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.